← Leaderboards
Gualberto Ruano
Genomas, Inc.
$7,434,649
Attributed
$7,434,649
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$6,186,955 · 5
AHRQ$1,247,694 · 1
By mechanism
R44$5,679,955 · 3
R01$1,247,694 · 1
R43$507,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseBiometryUniversitiesGenomeInstitutesResponseProgramsSmall Business Innovation Research GrantSingle Nucleotide PolymorphismGenotypeHospitalsGenesPublishingDiagnosticAlgorithmsRepositoryAdverse EffectsLaboratoriesPrototypePharmaceutical PreparationsCardiovascular SystemPredictive ModelingAccountingMedical
Grant awards (22)
Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT$249,537
R01 · FY2017 · HS · contact PI
Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT$249,539
R01 · FY2016 · HS · contact PI
Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT$249,539
R01 · FY2015 · HS · contact PI
Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT$249,539
R01 · FY2014 · HS · contact PI
Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT$249,540
R01 · FY2013 · HS · contact PI
System for DNA-Guided Optimization and Personalization of Statin Therapy$192,734
R44 · FY2013 · GM · contact PI
System for DNA-Guided Optimization and Personalization of Statin Therapy$641,098
R44 · FY2012 · GM · contact PI
System for DNA-Guided Optimization and Personalization of Statin Therapy$605,509
R44 · FY2011 · GM · contact PI
MRI DNA Biomarkers for Neuropsychiatric Disease$449,956
R44 · FY2011 · MH · contact PI
MRI DNA Biomarkers for Neuropsychiatric Disease$449,992
R44 · FY2010 · MH · contact PI
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics$497,546
R44 · FY2009 · MH · contact PI
MRI DNA Biomarkers for Neuropsychiatric Disease$450,001
R44 · FY2009 · MH · contact PI
DNA Diagnostic System for Statin Safety and Efficacy$338,062
R44 · FY2009 · GM · contact PI
DNA Diagnostic System for Statin Safety and Efficacy$231,120
R44 · FY2009 · GM · contact PI
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics$112,220
R44 · FY2009 · MH · contact PI
DNA Diagnostic System for Statin Safety and Efficacy$670,537
R44 · FY2008 · GM · contact PI
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics$448,660
R44 · FY2008 · MH · contact PI
DNA Diagnostic System for Statin Safety and Efficacy$143,338
R44 · FY2008 · GM · contact PI
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics$449,182
R44 · FY2007 · MH · contact PI
Physiogenomic Arrays for Clinical Neuropsychiatry$200,000
R43 · FY2006 · MH · contact PI
Physiogenomic Arrays for Clinical Neuropsychiatry$200,000
R43 · FY2005 · MH
Gene Markers: Antipsychotic-Induced Metabolic Syndrome$107,000
R43 · FY2005 · MH